Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
3.2 BPC-157 (Body Protection Compound-157) What it is
Plant-based choices such as tofu, lentils, and other legume options add protein along with fiber, which can support digestion and fullness
Stool softeners are a reasonable addition if dietary changes are insufficient
Going more than 14 days without a GLP-1 dose may require medical guidance before safely restarting your medication
However, not all forms are equal, and the way you take it matters more than the dosage on the label
Semaglutide Clinical Data The STEP trial program represents the most comprehensive clinical evaluation of any GLP-1 receptor agonist for weight management: STEP 1: 14.9% mean body weight loss over 68 weeks (Wilding et al., NEJM , 2021) STEP 3: 16.0% with intensive behavioral therapy over 68 weeks STEP 5: Sustained 15.2% weight loss maintained at 104 weeks with continued treatment SELECT trial: Demonstrated 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in addition to weight loss, establishing cardiovascular benefit (Lincoff et al., NEJM , 2023) The SELECT trial result is particularly significant because it demonstrated that semaglutide provides cardiovascular protection independent of weight loss, a benefit that has not been established for tesofensine
